RecruitingPhase 3NCT07288567
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
Sponsor
Bristol-Myers Squibb
Enrollment
166 participants
Start Date
Jan 29, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Eligibility
Min Age: 13 YearsMax Age: 17 Years
Inclusion Criteria3
- Diagnosis of schizophrenia as defined by the The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,Text Revision (DSM-5-TR) criteria, confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL) and experiencing symptoms of psychosis at screening (Visit 1).
- PANSS total score of at least 70 at screening (Visit 1) and randomization (Visit 2).
- Participant has a CGI-S score of ≥ 4 at screening (Visit 1) and randomization (Visit 2).
Exclusion Criteria5
- Any primary DSM-5-TR disorder other than schizophrenia within 12 months before screening.
- History or presence of clinically significant cardiovascular, pulmonary, hepatic impairment, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
- All grades of hepatic impairment (mild \[Child-Pugh Class A\], moderate \[Child-Pugh Class B\], and severe \[Child-Pugh Class C\]). Participants with known intellectual disability defined as an IQ less than 70; or, either clinical evidence or known social or school history indicative of intellectual disability.
- Any neurological disorder, except for Tourette's Syndrome.
- Participants who have either a systolic blood pressure (sBP) or diastolic blood pressure (dBP) meeting criteria for stage 2 HTN, regardless of the presence or absence of symptoms.
Interventions
DRUGKarXT
Specified dose on specified days
OTHERKarXT Matching Placebo
Specified dose on specified days
Locations(45)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07288567
Related Trials
Tolerability of MDMA in Schizophrenia
NCT057703751 location
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT0688278555 locations
Cerebellar Modulation of Cognition in Psychosis
NCT061077642 locations
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
NCT037940761 location
Cerebellar Stimulation and Cognitive Control
NCT032171101 location